We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ZYNYZ Specialised Therapeutics Alim Pty Ltd
Product name
ZYNYZ
Accepted date
Jun-2025
Active ingredients
retifanlimab
Proposed indication
ZYNYZ (retifanlimab) is used to treat squamous cell carcinoma of the anal canal (SCAC), a type of anal cancer (either alone or in combination with the anticancer medicines carboplatin and paclitaxel). It also used to treat Merkel Cell Carcinoma (a type of skin cancer).
Application type
A (new medicine)
Publication date
Jun-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.